Omeros Corp

Отворен

СекторЗдравеопазване

17.18 -0.81

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

16.17

Максимум

17.88

Ключови измерители

By Trading Economics

Приходи

-35M

51M

Продажби

9.9M

9.9M

P/E

Средно за сектора

11.641

57.002

EPS

0.57

Марж на печалбата

518.033

Служители

175

EBITDA

86M

57M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+140.7% upside

Дивиденти

By Acuity

Следващи печалби

12.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-53M

983M

Предишно отваряне

17.99

Предишно затваряне

17.18

Настроения в новините

By Acuity

57%

43%

286 / 340 Класиране в Healthcare

Omeros Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.08.2026 г., 23:06 ч. UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12.08.2026 г., 23:51 ч. UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11.08.2026 г., 23:41 ч. UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10.08.2026 г., 23:51 ч. UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8.08.2026 г., 00:02 ч. UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7.08.2026 г., 23:31 ч. UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6.08.2026 г., 23:01 ч. UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5.08.2026 г., 23:51 ч. UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4.08.2026 г., 23:02 ч. UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3.08.2026 г., 23:11 ч. UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1.08.2026 г., 00:01 ч. UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31.07.2026 г., 23:41 ч. UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30.07.2026 г., 16:06 ч. UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

29.07.2026 г., 18:58 ч. UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

28.07.2026 г., 19:16 ч. UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

27.07.2026 г., 21:01 ч. UTC

Omeros Corp shares are higher in after-market hours, following a broader market trend amid easing geopolitical tensions and declining oil prices.

24.07.2026 г., 19:26 ч. UTC

Omeros Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the movement.

22.07.2026 г., 18:46 ч. UTC

Omeros Corp shares are higher today, continuing an upward trend since Tuesday. Broader market dynamics are influenced by rising crude oil prices amid geopolitical tensions.

21.07.2026 г., 23:06 ч. UTC

Omeros Corp. shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average, marking three consecutive lower daily closes.

20.07.2026 г., 19:26 ч. UTC

Omeros Corp shares are higher today, despite an earlier pullback. The stock has stabilized since Friday's close within its one-month trading range.

Сравнение с други в отрасъла

Ценова промяна

Omeros Corp Прогноза

Ценова цел

By TipRanks

140.7% нагоре

12-месечна прогноза

Среден 33 USD  140.7%

Висок 33 USD

Нисък 33 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Omeros Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Настроение

By Acuity

286 / 340 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat